89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer

• DOI: 10.1007/s00259-014-2830-7
• Publication Date: 2014-08-20T05:46:01Z
• Authors: Neeta Pandit-Taskar; Joseph A. O’Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B. Solomon; Jeremy C. Durack; Jorge A. Carrasqu...; Robert A. Lefkowitz; Mithat Gonen; Jason S. Lewis; Jason P. Holland; Sarah M. Cheal; Victor E. Reuter; Joseph R. Osborne; Massimo F. Loda; Peter M. Smith-Jones; Wolfgang A. Weber; Neil H. Bander; Howard I. Scher; Michael J. Morris; Steven M. Larson
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Purpose Given the bone tropism of prostate cancer, conventional imaging modalities poorly identify or quantify metastatic disease. 89Zr-huJ591 positron emission tomography (PET) imaging was performed in patients with metastatic prostate cancer to analyze and validate this as an imaging biomarker for metastatic disease. The purpose of this initial study was to assess safety, biodistribution, normal organ dosimetry, and optimal imaging time post-injection for lesion detection.